1
|
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
|
Am J Respir Crit Care Med
|
2002
|
2.50
|
2
|
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
|
Nat Genet
|
2012
|
2.14
|
3
|
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
|
J Pediatr
|
2008
|
1.96
|
4
|
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
|
Proc Natl Acad Sci U S A
|
2006
|
1.95
|
5
|
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
|
J Clin Microbiol
|
2004
|
1.91
|
6
|
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
|
Hum Gene Ther
|
2006
|
1.78
|
7
|
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
|
J Cyst Fibros
|
2008
|
1.71
|
8
|
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
|
Am J Respir Crit Care Med
|
2002
|
1.70
|
9
|
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.
|
Pediatr Pulmonol
|
2004
|
1.64
|
10
|
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
|
Contemp Clin Trials
|
2009
|
1.53
|
11
|
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
|
J Clin Microbiol
|
2003
|
1.40
|
12
|
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
|
Pediatr Pulmonol
|
2010
|
1.24
|
13
|
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
|
Pediatr Pulmonol
|
2007
|
1.19
|
14
|
Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
|
Pediatr Pulmonol
|
2010
|
1.16
|
15
|
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
|
J Cyst Fibros
|
2012
|
1.05
|
16
|
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
|
Pediatr Pulmonol
|
2014
|
1.05
|
17
|
Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
|
Influenza Other Respir Viruses
|
2011
|
0.94
|
18
|
Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
|
Chest
|
2007
|
0.89
|
19
|
Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
|
J Aerosol Med Pulm Drug Deliv
|
2012
|
0.88
|
20
|
Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
|
J Cyst Fibros
|
2012
|
0.82
|
21
|
Upper thoracic shape in children with pectus excavatum: impact on lung function.
|
Pediatr Pulmonol
|
2012
|
0.80
|
22
|
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
|
Pediatr Pulmonol
|
2013
|
0.79
|
23
|
Correction: Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
|
PLoS Genet
|
2015
|
0.75
|